AKT1 and osteoporosis: Combining network pharmacology analysis with experimental verification in vivo and in vitro, we found that EXD may attenuate osteoporosis at least partially by reducing TNF-α production and regulating the Akt/Nrf2/HO-1 signaling pathway.